New Chairman of the Board for Oncopeptides AB

2010-04-19

STOCKHOLM, April 19, 2010 ‐ Oncopeptides AB, a Karolinska Development portfolio company, today announced that Alan Hulme was elected Chairman of the Board at the annual general meeting. Mr Hulme has over 30 years experience in the life science business and wide experience in many sectors and geographic locations.

"We are fortunate to have Alan as the Chairman of the Board and I look forward to his contribution to the development of the company" says Dr Jack Spira CEO of Oncopeptides AB.

Conny Bogentoft, CEO of Karolinska Development added "Alan's vast experience in business development will be of great value to the Company as it now enters into later development phases. This will help Oncopeptides fulfill its goals, which will further strengthen the Karolinska Development portfolio." Alan Hulme has been involved in the development of many businesses within the life sciences sector ‐ covering biotechnology, diagnostics and medical devices - and, operating from his base in London, has been engaged in a range of international corporate development activities with venture backed companies in the sector.

About Oncopeptides AB
Oncopeptides is a privately held company developing pharmaceuticals to treat cancer. The Company has proprietary technology based on creating pro‐drugs with increased efficacy of already known compounds. The lead substance, called J1, is presently in a phase IIa clinical trial. Oncopeptides is part of the Karolinska Development portfolio. www.oncopeptides.se